World Refractory Leukemia Pipeline Insights 2016 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3jtc2v/refractory) has announced the addition of the "Refractory Leukemia-Pipeline Insights, 2016" report to their offering.

Refractory Leukemia-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Refractory Leukemia. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Refractory Leukemia.

The report also assesses the Refractory Leukemia therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Refractory Leukemia
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Refractory Leukemia pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Refractory Leukemia and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Refractory Leukemia Overview
  2. Refractory Leukemia Pipeline Therapeutics
  3. Refractory Leukemia Therapeutics under Development by Companies
  4. Refractory Leukemia Filed and Phase III Products
  5. Comparative Analysis
  6. Refractory Leukemia Phase II Products
  7. Refractory Leukemia Phase I and IND Filed Products
  8. Refractory Leukemia Discovery and Pre-Clinical Stage Products
  9. Refractory Leukemia - Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Refractory Leukemia - Discontinued Products
  15. Refractory Leukemia - Dormant Products
  16. Companies Involved in Therapeutics Development for Refractory Leukemia

For more information visit http://www.researchandmarkets.com/research/3jtc2v/refractory

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Leukemia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Leukemia